Cancer has been a major global health problem due to its high morbidity and mortality.
While many chemotherapy agents have been studied and applied in clinical trials or in …

Background Immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer
(NSCLC) have been rapidly evolving. ICIs are likely to be more effective but also lead to …

Background The IMpower150 trial found that adding atezolizumab to the combination of
bevacizumab and chemotherapy improved survival for patients with metastatic …

Background: In the CASPIAN trial, durvalumab 1 chemotherapy demonstrated significant
improvements in overall survival compared with chemotherapy alone in patients with …

Objective: To describe the cost-effectiveness of pembrolizumab plus chemotherapy
(carboplatin and paclitaxel or nab-paclitaxel; P+ C) in metastatic, squamous, non-small-cell …

Aim: This analysis aimed to evaluate the cost–effectiveness of pembrolizumab monotherapy
as first-line treatment in advanced non-small-cell lung cancer patients with a programmed …

Importance Immune checkpoint inhibitor combination therapy has recently become the
standard of care for first-line treatment of metastatic nonsquamous non–small cell lung …

Objectives A double-blind, placebo-controlled, phase 3 trial has shown atezolizumab plus
chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer could …

Background Adding atezolizumab to carboplatin/nab-paclitaxel improved progression-free
survival and overall survival in patients with advanced non-squamous non-small-cell lung …

Background The KEYNOTE‐024 trial demonstrated that pembrolizumab, a PD‐1 inhibitor,
significantly improves progression‐free survival (PFS) and overall survival (OS) in selected …